WO2013134142A1

WO2013134142A1 - Inhibitors of human immunodeficiency virus replication

Info

Publication number: WO2013134142A1
Application number: PCT/US2013/028903
Authority: WO
Inventors: Zhizhen Barbara Zheng; Stanley D'andrea; David R. Langley; B. Narasimhulu Naidu
Original assignee: Bristol Myers Squibb Co
Current assignee: Bristol Myers Squibb Co
Priority date: 2012-03-06
Filing date: 2013-03-04
Publication date: 2013-09-12
Anticipated expiration: 2014-09-06
Also published as: US9006235B2; ES2610708T3; EP2822950B1; EP2822950A1; US20130237499A1

Description

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application Serial Number 61/607, 184 filed March 6, 2012.

BACKGROUND OF THE INVENTION

The disclosure generally relates to compounds, compositions, and methods for the treatment of human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

Human immunodeficiency virus (HIV) has been identified as the etiological agent responsible for acquired immune deficiency syndrome (AIDS), a fatal disease characterized by destruction of the immune system and the inability to fight off life threatening opportunistic infections. Recent statistics indicate that as many as 33 million people worldwide are infected with the virus (UNAIDS: Report on the Global HIV/AIDS Epidemic, December 1998). In addition to the large number of individuals already infected, the virus continues to spread. Estimates from 1998 point to close to 6 million new infections in that year alone. In the same year there were approximately 2.5 million deaths associated with HIV and AIDS.

There are currently a number of antiviral drugs available to combat the infection. These drugs can be divided into classes based on the viral protein they target or their mode of action. In particular, saquinavir, indinavir, ritonavir, nelfinavir atazanavir darunavir, amprenavir, fosamprenavir, lopinavir and tipranavir are competitive inhibitors of the aspartyl protease expressed by HIV. Zidovudine, didanosine, stavudine, lamivudine, zalcitabine, emtricitibine, tenofovir and abacavir are nucleos(t)ide reverse transcriptase inhibitors that behave as substrate mimics to halt viral cDNA synthesis. The non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, efavirenz and etravirine inhibit the synthesis of viral cDNA via a non-competitive (or uncompetitive) mechanism. Enfuvirtide and maraviroc inhibit the entry of the virus into the host cell. An HIV integrase inhibitor, raltegravir (MK-0518, Isentress^®), has also been approved for use in treatment experienced patients, and it is clear that this class of inhibitors is very effective as part of a combination regimen containing HIV inhibitors of different classes.

Used alone, these drugs are effective in reducing viral replication: however, the effect is only temporary as the virus readily develops resistance to all known agents used as monotherapy. However, combination therapy has proven very effective at both reducing virus and suppressing the emergence of resistance in a number of patients. In the US, where combination therapy is widely available, the number of HIV-related deaths has dramatically declined (Palella, F. J.; Delany, K. M.; Moorman, A. C; Loveless, M. O.; Furher, J.; Satten, G. A.; Aschman, D. J.; Holmberg, S. D. N. Engl. J. Med. 1998, 338, 853-860).

Unfortunately, not all patients are responsive and a large number fail this therapy. In fact, initial studies suggest that approximately 30-50% of patients ultimately fail at least one drug in the suppressive combination. Treatment failure in most cases is caused by the emergence of viral resistance. Viral resistance in turn is caused by the replication rate of HIV- 1 during the course of infection combined with the relatively high viral mutation rate associated with the viral polymerase and the lack of adherence of HIV-infected individuals in taking their prescribed medications. Clearly, there is a need for new antiviral agents, preferably with activity against viruses already resistant to currently approved drugs. Other important factors include improved safety and a more convenient dosing regimen than many of the currently approved drugs.

Compounds which inhibit HIV replication have been disclosed. See

WO2007131350, WO2009062285, WO2009062288, WO2009062289,

WO2009062308, WO2010130034, WO2010130842, WO2011015641,

WO2011076765, WO2012003497 and WO2012003498. The invention provides technical advantages, for example, the compounds are novel and are useful in the treatment of HIV. Additionally, the compounds provide advantages for pharmaceutical uses, for example, with regard to one or more of their mechanism of action, binding, inhibition efficacy, target selectivity, solubility, safety profiles, or bioavailability.

DESCRIPTION OF THE INVENTION

The invention encompasses compounds of Formula I, including

pharmaceutically acceptable salts, their pharmaceutical compositions, and their inhibiting HIV integrase and treating those infected with HIV or AIDS.

One aspect of the invention is a compound of Formula I

I where: R¹ is N(R⁶)(R⁷); hydrogen, halo, or alkyl;

R³ is alkyl, cycloalkyl, or Ar¹;

R⁴ is alkyl or haloalkyl;

R⁵ is alkyl; R⁶ is hydrogen, alkyl, haloalkyl, (cycloalkyl)alkyl, (Ar²)alkyl, cycloalkyl,

(alkyl)cycloalkyl, (Ar²)cycloalkyl, (alkyl)CO, (haloalkyl)CO, ((cycloalkyl)alkyl)CO, (Ar²)CO, ((Ar²)alkyl)CO, ((Ar²)alkyl)OCO, ((Ar²)alkyl)NHCO, or

((Ar²)alkyl)COCO;

or R⁶ is ((trialkylsilyl)alkyl)OCO, (benzyloxy)alkylCO, (phenoxyalkyl)CO,

(isoindolinedionyl)alkyl)CO, (((dialkyl)cycloalkoxy)alkyl)CO, (phenoxyalkyl)CO, or (dihalobenzodioxolyl)CO;

R⁷ is hydrogen or alkyl; or N(R⁶)(R⁷) taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl, homopiperazinyl, or homomorpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, haloalkyl, hydroxy, alkoxy, or haloalkoxy; and

Ar¹ is phenyl, pyridinyl, indanyl, naphthyl, tetrahydronaphthalenyl, benzofuranyl, dihydrobenzofuranyl, benzodioxyl, chromanyl, isochromanyl, benzodioxanyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl,

dihydrobenzoxazinyl, indolyl, dihydroindolyl, benzthiazolyl, or benzothiazolyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, hydroxy, alkoxy, haloalkoxy, phenoxy, benzyloxy, thioalkyl, and acetamido;

Ar² is phenyl, biphenyl, pyrazolyl, indolyl, or fluorenonyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, benzyloxy, and haloalkoxy; or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a compound of formula I where:

R¹ is N(R⁶)(R⁷); R² is hydrogen;

R³ is Ar¹;

R⁴ is alkyl;

R⁵ is alkyl;

R⁶ is hydrogen, alkyl, haloalkyl, (cycloalkyl)alkyl, (Ar²)alkyl, cycloalkyl, (alkyl)CO, ((cycloalkyl)alkyl)CO, (Ar²)CO, ((Ar²)alkyl)CO, ((Ar²)alkyl)OCO,

((Ar²)alkyl)NHCO, or ((Ar²)alkyl)COCO; or R⁶ is ((trialkylsilyl)alkyl)OCO, (benzyloxy)alkylCO, (phenoxyalkyl)CO,

R⁷ is hydrogen or alkyl; or where N(R⁶)(R⁷) taken together is pyrrolidinyl or piperidinyl, and is substituted with 0-3 substituents selected from halo, alkyl, haloalkyl, hydroxy, alkoxy, and haloalkoxy; Ar¹ is chromanyl substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, hydroxy, alkoxy, haloalkoxy, phenoxy, benzyloxy, thioalkyl, and acetamido; and Ar² is phenyl, pyrazolyl, indolyl, or fluorenonyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, benzyloxy, and haloalkoxy;

or a pharmaceutically acceptable salt thereof. Another aspect of the invention is a compound of formula I where R² is hydrogen.

Another aspect of the invention is a compound of formula I where R³ is Ar¹.

Another aspect of the invention is a compound of formula I where R⁴ is alkyl.

Another aspect of the invention is a compound of formula I where R⁶ is hydrogen, alkyl, haloalkyl, (cycloalkyl)alkyl, (Ar²)alkyl, cycloalkyl, (alkyl)CO,

((cycloalkyl)alkyl)CO, (Ar²)CO, ((Ar²)alkyl)CO, ((Ar²)alkyl)OCO,

((Ar²)alkyl)NHCO, or ((Ar²)alkyl)COCO.

Another aspect of the invention is a compound of formula I where N(R⁶)(R⁷) taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl, homopiperazinyl, or homomorpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, haloalkyl, hydroxy, alkoxy, or haloalkoxy.

Another aspect of the invention is a compound of formula I where N(R⁶)(R⁷) taken together is pyrrolidinyl or piperidinyl, and is substituted with 0-3 substituents selected from halo, alkyl, haloalkyl, hydroxy, alkoxy, and haloalkoxy. Another aspect of the invention is a compound of formula I where Ar¹ is chromanyl substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, hydroxy, alkoxy, haloalkoxy, phenoxy, benzyloxy, thioalkyl, and acetamido. Another aspect of the invention is a compound of formula I where Ar² is phenyl, pyrazolyl, indolyl, or fluorenonyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, benzyloxy, and haloalkoxy.

Another aspect of the invention is a compound of formula I where Ar² is phenyl substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, benzyloxy, and haloalkoxy. For a compound of Formula I, the scope of any instance of a variable substituent, including R¹, R², R³, R⁴, R⁵, R⁶, R⁷, Ar¹, and Ar², can be used independently with the scope of any other instance of a variable substituent. As such, the invention includes combinations of the different aspects. Unless specified otherwise, these terms have the following meanings. "Halo" includes fluoro, chloro, bromo, and iodo. "Alkyl" means a straight or branched alkyl group composed of 1 to 10 carbons, more preferably 1 to 6 carbons. "Alkenyl" means a straight or branched alkyl group composed of 2 to 10 carbons, more preferably 2 to 6 carbons, with at least one double bond. "Alkynyl" means a straight or branched alkyl group composed of 2 to 10 carbons, more preferably 2 to 6 carbons, with at least one triple bond. "Cycloalkyl" means a monocyclic ring system composed of 3 to 7 carbons. "Haloalkyl" and "haloalkoxy" include all halogenated isomers from monohalo to perhalo. Terms with a hydrocarbon moiety (e.g. alkoxy) include straight and branched isomers for the hydrocarbon portion. "Aryl" means a monocyclic or bicyclic aromatic hydrocarbon groups having 6 to 12 carbon atoms, or a bicyclic fused ring system wherein one or both of the rings is a phenyl group.

Bicyclic fused ring systems consist of a phenyl group fused to a four- to six- membered aromatic or non-aromatic carbocyclic ring. Representative examples of aryl groups include, but are not limited to, indanyl, indenyl, naphthyl, phenyl, and tetrahydronaphthyl. "Heteroaryl" means a 5 to 7 membered monocyclic or 8 to 1 1 membered bicyclic aromatic ring system with 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Parenthetic and multiparenthetic terms are intended to clarify bonding relationships to those skilled in the art. For example, a term such as ((R)alkyl) means an alkyl substituent further substituted with the substituent R.

The invention includes all pharmaceutically acceptable salt forms of the compounds. Pharmaceutically acceptable salts are those in which the counter ions do not contribute significantly to the physiological activity or toxicity of the compounds and as such function as pharmacological equivalents. These salts can be made according to common organic techniques employing commercially available reagents. Some anionic salt forms include acetate, acistrate, besylate, bromide, chloride, citrate, fumarate, glucouronate, hydrobromide, hydrochloride, hydroiodide, iodide, lactate, maleate, mesylate, nitrate, pamoate, phosphate, succinate, sulfate, tartrate, tosylate, and xinofoate. Some cationic salt forms include ammonium, aluminum, benzathine, bismuth, calcium, choline, diethylamine, diethanolamine, lithium, magnesium, meglumine, 4-phenylcyclohexylamine, piperazine, potassium, sodium, tromethamine, and zinc.

Some of the compounds of the invention exist in stereoisomeric forms. The invention includes all stereoisomeric forms of the compounds including enantiomers and diastereromers. Methods of making and separating stereoisomers are known in the art. The invention includes all tautomeric forms of the compounds. The invention includes atropisomers and rotational isomers.

The invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include ¹³C and ¹⁴C. Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. Such compounds may have a variety of potential uses, for example as standards and reagents in determining biological activity. In the case of stable isotopes, such compounds may have the potential to favorably modify biological, pharmacological, or pharmacokinetic properties.

Biological Methods Inhibition of HIV replication. A recombinant NL-Rluc virus was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. The NL-RLuc virus was prepared by co-transfection of two plasmids, pNLRLuc and pVSVenv. The pNLRLuc contains the NL-Rluc DNA cloned into pUC18 at the Pvull site, while the pVSVenv contains the gene for VSV G protein linked to an LTR promoter. Transfections were performed at a 1 :3 ratio of pNLRLuc to pVSVenv in 293T cells using the LipofectAMINE PLUS kit from Invitrogen (Carlsbad, CA) according to the manufacturer, and the pseudotype virus generated was titered in MT-2 cells. For susceptibility analyses, the titrated virus was used to infect MT-2 cells in the presence of compound, and after 5 days of incubation, cells were processed and quantitated for virus growth by the amount of expressed luciferase. This provides a simple and easy method for quantitating the extent of virus growth and consequently, the antiviral activity of test compounds. Luciferase was quantitated using the Dual Luciferase kit from Promega (Madison, WI).

Susceptibility of viruses to compounds was determined by incubation in the presence of serial dilutions of the compound. The 50% effective concentration (EC₅₀) was calculated by using the exponential form of the median effect equation where (Fa) = 1/[1+ (ED₅₀/drug conc.)^m] (Johnson VA, Byington RT. Infectivity Assay. In Techniques in HIV Research, ed. Aldovini A, Walker BD. 71-76. New York: Stockton Press.1990). The anti-viral activity of compounds was evaluated under three serum conditions, 10% FBS, 15mg/ml human serum albumin/10% FBS or 40% human serum/5% FBS, and the results from at least 2 experiments were used to calculate the EC5₀ values. Results are shown in Table 1. Activity equal to A refers to a compound having an EC5₀ < 100 nM, while B and C denote compounds having an EC₅₀ between 100 nM and luM (B) or >luM (C). Table 1.

Example Activity ΕΟ₅₀ (μΜ)

31 A

32 C 6.41

33 A 0.06

34 A

35 A

36 A

37 A

38 B 0.30

39 A

40 A

41 A 0.05

42 A

43 A

44 C 1.60

45 A

46 C 2.57

47 A

48 B 0.34

49 B

50 A 0.06

51 B

52 A

Pharmaceutical Composition and Methods of Use

The compounds of this invention inhibit HIV replication. Accordingly, another aspect of the invention is a method for treating HIV infection in a human patient comprising administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable carrier. Another aspect of the invention is the use of a compound of formula I in the manufacture of a medicament for the treatment of AIDS or HIV infection.

Another aspect of the invention is a method for treating HIV infection in a human patient comprising the administration of a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, with a therapeutically effective amount of at least one other agent used for treatment of AIDS or HIV infection selected from the group consisting of nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors.

Another aspect of the invention is a method wherein the agent is a nucleoside HIV reverse transcriptase inhibitor.

Another aspect of the invention is a method wherein the nucleoside HIV reverse transcriptase inhibitor is selected from the group consisting of abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine, and zidovudine, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a method wherein the agent is a non- nucleoside HIV reverse transcriptase inhibitor. Another aspect of the invention is a method wherein the non-nucleoside HIV reverse transcriptase inhibitor is selected from the group consisting of delavirdine, efavirenz, and nevirapine, or a pharmaceutically acceptable thereof.

Another aspect of the invention is a method wherein the agent is an HIV protease inhibitor.

Another aspect of the invention is a method wherein the HIV protease inhibitor is selected from the group consisting of amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and fosamprenavir, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a method wherein the agent is an HIV fusion inhibitor.

Another aspect of the invention is a method wherein the HIV fusion inhibitor is enfuvirtide or T-1249, or a pharmaceutically acceptable salt thereof. Another aspect of the invention is a method wherein the agent is an HIV attachment inhibitor.

Another aspect of the invention is a method wherein the agent is a CCR5 inhibitor.

Another aspect of the invention is a method wherein the CCR5 inhibitor is selected from the group consisting of Sch-C, Sch-D, TAK-220, PRO- 140, and UK- 427,857, or a pharmaceutically acceptable salt thereof. Another aspect of the invention is a method wherein the agent is a CXCR4 inhibitor.

Another aspect of the invention is a method wherein the CXCR4 inhibitor is AMD-3100, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a method wherein the agent is an HIV budding or maturation inhibitor.

Another aspect of the invention is a method wherein the budding or maturation inhibitor is PA-457, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a method wherein the agent is an HIV integrase inhibitor. Another aspect of the invention is a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, with at least one other agent used for treatment of AIDS or HIV infection selected from the group consisting of nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors, and a pharmaceutically acceptable carrier.

Another aspect of the invention is the composition wherein the agent is a nucleoside HIV reverse transcriptase inhibitor.

Another aspect of the invention is the composition wherein the nucleoside HIV transcriptase inhibitor is selected from the group consisting of abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine, and zidovudine, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is the composition wherein the agent is a non- nucleoside HIV reverse transcriptase inhibitor.

Another aspect of the invention is the composition wherein the non- nucleoside HIV reverse transcriptase inhibitor is selected from the group consisting of delavirdine, efavirenz, and nevirapine, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is the composition wherein the agent is an HIV protease inhibitor.

Another aspect of the invention is the composition wherein the HIV protease inhibitor is selected from the group consisting of amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and fosamprenavir, or a pharmaceutically acceptable salt thereof. Another aspect of the invention is the composition wherein the agent is an HIV fusion inhibitor.

Another aspect of the invention is the composition method wherein the HIV fusion inhibitor is enfuvirtide or T-1249, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is the composition wherein the agent is an HIV attachment inhibitor.

Another aspect of the invention is the composition wherein the agent is a CCR5 inhibitor.

Another aspect of the invention is the composition wherein the CCR5 inhibitor is selected from the group consisting of Sch-C, Sch-D, TAK-220, PRO- 140, and UK-427,857, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a method wherein the agent is a CXCR4 inhibitor.

Another aspect of the invention is a method wherein the CXCR4 inhibitor is AMD-3100 or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is the composition wherein the agent is an HIV budding or maturation inhibitor.

Another aspect of the invention is the composition wherein the budding or maturation inhibitor is PA-457, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is the composition wherein the agent is an HIV integrase inhibitor. "Combination," "coadministration," "concurrent" and similar terms referring to the administration of a compound of Formula I with at least one anti-HIV agent mean that the components are part of a combination antiretroviral therapy or highly active antiretroviral therapy (HAART) as understood by practitioners in the field of AIDS and HIV infection.

"Therapeutically effective" means the amount of agent required to provide a meaningful patient benefit as understood by practitioners in the field of AIDS and HIV infection. In general, the goals of treatment are suppression of viral load, restoration and preservation of immunologic function, improved quality of life, and reduction of HIV-related morbidity and mortality.

"Patient" means a person infected with the HIV virus and suitable for therapy as understood by practitioners in the field of AIDS and HIV infection.

"Treatment," "therapy," "regimen," "HIV infection," "ARC," "AIDS" and related terms are used as understood by practitioners in the field of AIDS and HIV infection. The compounds of this invention are generally given as pharmaceutical compositions comprised of a therapeutically effective amount of a compound of Formula I or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier and may contain conventional excipients. A therapeutically effective amount is that which is needed to provide a meaningful patient benefit. Pharmaceutically acceptable carriers are those conventionally known carriers having acceptable safety profiles. Compositions encompass all common solid and liquid forms including capsules, tablets, losenges, and powders as well as liquid suspensions, syrups, elixers, and solutions. Compositions are made using common formulation techniques, and conventional excipients (such as binding and wetting agents) and vehicles (such as water and alcohols) are generally used for compositions. See, for example,

Remington 's Pharmaceutical Sciences, 17th edition, Mack Publishing Company, Easton, PA (1985). Solid compositions are normally formulated in dosage units and compositions providing from about 1 to 1000 mg of the active ingredient per dose are preferred. Some examples of dosages are 1 mg, 10 mg, 100 mg, 250 mg, 500 mg, and 1000 mg. Generally, other antiretroviral agents will be present in a unit range similar to agents of that class used clinically. Typically, this is 0.25-1000 mg/unit.

Liquid compositions are usually in dosage unit ranges. Generally, the liquid composition will be in a unit dosage range of 1-100 mg/mL. Some examples of dosages are 1 mg/mL, 10 mg/mL, 25 mg/mL, 50 mg/mL, and 100 mg/mL.

Generally, other antiretroviral agents will be present in a unit range similar to agents of that class used clinically. Typically, this is 1-100 mg/mL.

The invention encompasses all conventional modes of administration; oral and parenteral methods are preferred. Generally, the dosing regimen will be similar to other antiretroviral agents used clinically. Typically, the daily dose will be 1-100 mg/kg body weight daily. Generally, more compound is required orally and less parenterally. The specific dosing regime, however, will be determined by a physician using sound medical judgement. The invention also encompasses methods where the compound is given in combination therapy. That is, the compound can be used in conjunction with, but separately from, other agents useful in treating AIDS and HIV infection. Some of these agents include HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV cell fusion inhibitors, HIV integrase inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV non-nucleoside reverse transcriptase inhibitors, HIV protease inhibitors, budding and maturation inhibitors, immunomodulators, and anti- infectives. In these combination methods, the compound of Formula I will generally be given in a daily dose of 1-100 mg/kg body weight daily in conjunction with other agents. The other agents generally will be given in the amounts used therapeutically. The specific dosing regime, however, will be determined by a physician using sound medical judgement. Synthetic Methods

The compounds of this invention can be made by various methods known in the art including those of the following schemes and in the specific embodiments section. The structure numbering and variable numbering shown in the synthetic schemes are distinct from, and should not be confused with, the structure or variable numbering in the claims or the rest of the specification. The variables in the schemes are meant only to illustrate how to make some of the compounds of this invention. The disclosure is not limited to the foregoing illustrative examples and the examples should be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing examples, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced.

Abbreviations used in the schemes and examples generally follow

conventions used in the art. Chemical abbreviations used in the specification and examples are defined as follows: "KHMDS" for potasium bis(trimethylsilyl)amide; "DMF" for N,N-dimethylformamide; "HATU"for 0-(t-Azabenzotriazol-l-yl)- Ν,Ν,Ν',Ν'-tetramethyluronium hexafluorophosphate, "MeOH" for methanol; "Ar" for aryl; "TFA" for trifluoroacetic acid, "DMSO" for dimethylsulfoxide; "h" for hours; "rt" for room temperature or retention time (context will dictate); "min" for minutes; "EtOAc" for ethyl acetate; "THF" for tetrahydrofuran; "Et20" for diethyl ether; "DMAP" for 4-dimethylaminopyridine; "DCE" for 1,2-dichloroethane; "ACN" for acetonitrile; "DME" for 1,2-dimethoxy ethane; "HOBt" for 1- hydroxybenzotriazole hydrate; and "DIEA" for diisopropylethylamine.

Abbreviations as used herein, are defined as follows: "1 x" for once, "2 x" for twice, "3 x" for thrice, "°C" for degrees Celsius, "eq" for equivalent or equivalents, "g" for gram or grams, "mg" for milligram or milligrams, "L" for liter or liters, "mL" for milliliter or milliliters, "μΕ" for microliter or microliters, "N" for normal, "M" for molar, "mmol" for millimole or millimoles, "atm" for atmosphere, "psi" for pounds per square inch, "cone." for concentrate, "sat" or "sat'd " for saturated, "MW" for molecular weight, "mp" for melting point, "ee" for enantiomeric excess, "MS" or "Mass Spec" for mass spectrometry, "ESI" for electrospray ionization mass spectroscopy, "HR" for high resolution, "HRMS" for high resolution mass spectrometry , "LCMS" for liquid chromatography mass spectrometry, "HPLC" for high pressure liquid chromatography, "RP HPLC" for reverse phase HPLC, "TLC" or "tic" for thin layer chromatography, "NMR" for nuclear magnetic resonance spectroscopy, for proton, "δ" for delta, "s" for singlet, "d" for doublet, "t" for triplet, "q" for quartet, "m" for multiplet, "br" for broad, "Hz" for hertz, and "a", "β", "R", "S", "E", and "Z" are stereochemical designations familiar to one skilled in the art.

Some compounds can be synthesized from an appropriately substituted heterocycle 1-1 according to Scheme I, Compound 1-1 and 1-2 are commercially availiable or synthesized by reactions well known in the art. Intermediates 1-3 can be prepared by procedure well known in the art or as set forth in the examples below using compound 1-1 and compound 1-2. Intermediates 1-3 are convenietly transformed to intermediates 1-5 via intermediates 1-4 using conditions well-known to those skilled in the art. Intermedates 1-5 are oxidized to intermediates 1-6 by reactions well-known in the art, including but not limited to Davis oxidation.

Intermediates 1-6 are oxidized to intermediates 1-7 by a well-known conditions, including but not limited to Dess-Martin oxidation. Intermediates 1-7 are reduced to chiral intermediates 1-8 using well-known conditions in the presence of catalytic chiral ligands. Intermediates 1-8 are converted to the intermediates 1-9 by well- known conditions, including but not limited to tertiary-butyl acetate and perchloric acid. Intermediates 1-9 are conveniettly transformed to intermediates 1-10 using conditions well-known in the art, including but not limited to the Suzuki coupling between intermediates 1-9 and R4-B(OR)2. The boronate or boronic acid coupling reagents are commercially availible or are prepared by reactions well-known to those skilled in the art (PCT Appln. WO20090662285). The intermediates 1-10 are regioselectively converted to intermediates 1-11 by methods well-known in the art. Intermediates 1-11 are convenitely converted to intermediates 1-12 by conditions well-known to those skilled in the art, including but not limited to DPPA and appropriate base. Intermediates 1-12 are transformed to intermediates 1-13 using conditions well-known to those skilled in the art. Hydrolysis of intermediates 1-13 using the conditions well known to those skilled in the art provided the carboxylic acids 1-14. The intermediates 1-14 were transformed to final compounds 1-15 by conditions well known in the literature. In addition, the intermediates 1-14 could also be transformed to final compound 1-16 by reductive alkylation using conditions well to those skilled in art. The compounds described herein were purified by the methods well known to those skilled in art by normal phase column chromatography on silica gel column using appropriate solvent system described. All preparative HPLC purifications mentioned in this experimentation section were carried out gradient elution either on Sunfire Prep C18 ODB column (5 μιη; 19 X 100 mm) or Waters Xbridge column (5 μΜ; 19 X 100 mm) using the following mobile phases. For SunFire column mobile phase A: 9: 1 H₂0/acetonitrile with 10 mM NH₄OAc and mobile phase B : A: 9: 1 acetonitrile/H20 with: 10 mM NH₄OAc. For Waters Xbride column mobile phase A: water with 20 mM NH₄OAc and mobile phase B: 95:5 MeOH/H₂0 with 20 mM NH₄OAc.

Scheme I.

5

Ethyl 6-(2-ethoxy-2-oxoethyl)-7-hydroxy-5-methylpyrazolo[l,5-a]pyrimidine- 2-carboxylate. A suspension of ethyl 5-amino-lH-pyrazole-3-carboxylate (35.5 g, 229 mmol, prepared according to WO 2008015271), diethyl 2-acetylsuccinate (51.2 niL, 275 mmol) and TsOH»H₂0 (0.218 g, 1.144 mmol) in o-xylene (500 mL) was refluxed using a Dean-Stork condensor for 5 h. (Note: The suspension turned into a clear homogeneous solution and then in about 15 min a yellow solid started precipitated out of solution). Then, the reaction mixture was cooled, diluted with hexanes (250 mL), filtered, washed with hexanes and dried to afford ethyl 6-(2- ethoxy-2-oxoethyl)-7-hydroxy-5-methylpyrazolo[l,5-a]pyrimidine-2-carboxylate (53 g, 75 % yield) as light yellow solid. 1H NMR (500 MHz, DMSO-d₆) δ 12.61 (br. s., 1H), 6.49 (s, 1H), 4.34 (q, J= 7.1 Hz, 2H), 4.09 (q, J= 7.1 Hz, 2H), 3.57 (s, 2H), 2.34 (s, 3H), 1.33 (t, J= 7.2 Hz, 3H), 1.19 (t, J= 7.0 Hz, 3H). LCMS (M+H) = 308.04.

Ethyl 7-chloro-6-(2-ethoxy-2-oxoethyl)-5-methylpyrazolo[ 1, 5-a] pyrimidine-2- carboxylate. A mixture of ethyl 6-(2-ethoxy-2-oxoethyl)-7-hydroxy-5- methylpyrazolo[l,5-a]pyrimidine-2-carboxylate (25 g, 81 mmol), and N,N- dimethylaniline (20.6 mL, 163 mmol) in POCl₃ (100 mL) was heated at 120 °C for 3 h. Then the reaction was cooled to rt and concentrated in vacuo to half the volume. It was poured into a large quantity of ice water and stirred for 20 min. Precepitates formed and were collected by filtration. This solid was dissolved in ethyl acetate (1 L) and washed with water. The aqueous phase was back-extracted with ethyl acetate and the combined organic layers were washed with brine (200 mL), dried (Na₂S0₄), filtered and concentrated in vacuo. The crude was then triturated with EtOAc/hexane to afford ethyl 7-chloro-6-(2-ethoxy-2-oxoethyl)-5-methylpyrazolo[l,5-a]pyrimidine- 2-carboxylate (22 g, 67.5 mmol, 83 % yield) as light yellow solid. 1H NMR (500 MHz, CDC1₃) δ 7.21 (s, 1H), 4.52 (q, J= 7.2 Hz, 2H), 4.24 (q, J= 7.2 Hz, 2H), 3.94 (s, 2H), 2.66 (s, 3H), 1.48 (t, J= 7.0 Hz, 3H), 1.30 (t, J= 7.2 Hz, 3H). LCMS (M+H) = 326.2.

Ethyl 6-(2-ethoxy-2-oxoethyl)-7-iodo-5-methylpyrazolo[l,5-a]pyrimidine-2- carboxylate. Ethyl 7-chloro-6-(2-ethoxy-2-oxoethyl)-5-methylpyrazolo[l,5- a]pyrimidine-2-carboxylate (5 g, 15.35 mmol) and sodium iodide (9.20 g, 61.4 mmol) were suspended in acetonitrile (80 mL) and the resulting mixture was heated at 80°C for 2 h. At this point LCMS indicated completion of the reaction and appearance of the desired product. After cooling to rt, the reaction mixture was diluted with ethyl acetate and washed with water and aqueous a₂S₂0₃. The organic phase was dried (Na₂S0₄), filtered and concentrated in vacuo. The crude product was triturated with ethyl acetate/hexane to afford ethyl 6-(2-ethoxy-2-oxoethyl)-7- iodo-5-methylpyrazolo[l,5-a]pyrimidine-2 -carboxylate (5.7 g, 13.7 mmol, 89 % yield) as an off-white solid. 1H NMR (500 MHz, CDC1₃) δ 7.32 (s, 1H), 4.51 (d, J= 7.0 Hz, 2H), 4.25 (d, J= 7.0 Hz, 2H), 4.02 (s, 2H), 2.68 (s, 3H), 1.48 (t, J= 7.2 Hz, 3H), 1.31 (t, J= 7.2 Hz, 3H). LCMS (M+H) = 418.2.

Ethyl 6-(2-ethoxy-l-hydroxy-2-oxoethyl)-7-iodo-5-methylpyrazolo[l,5- aJpyrimidine-2-carboxylate. To a stirred solution of 0.9M KHMDS/THF (39.1 mL, 35.2 mmol) in THF (100 mL) at -78 °C was added a THF (50 mL) solution of ethyl 6-(2-ethoxy-2-oxoethyl)-7-iodo-5-methylpyrazolo[l,5-a]pyrimidine-2 -carboxylate (11.3 g, 27.1 mmol) over the course of 5 min. After 30 min, a THF (50 mL) solution of 3-phenyl-2-(phenylsulfonyl)-l,2-oxaziridine (9.20 g, 35.2 mmol) was added to the red reaction mixture and stirring was continued for an additional 30 min at -78 °C. Then, the resulting orange reaction mixture was quenched with sat. aq. NH₄C1 (50 mL), diluted with EtOAc (200 mL), washed with water (100 mL), brine (100 mL), dried ( a₂S0₄), filtered and concentrated in vacuo to give a solid. This solid was triturated with small amount of ethyl acetate and solids were filtered, washed with hexanes and dried under high vacuum to afford ethyl 6-(2-ethoxy-l-hydroxy-2- oxoethyl)-7-iodo-5-methylpyrazolo[l,5-a]pyrimidine-2-carboxylate (7.3 g, 16.85 mmol, 62.2 % yield) as light yellow solid. IH NMR (500 MHz, CDC1₃) δ 7.33 (s, IH), 5.75 (d, J= 2.1 Hz, IH), 4.52 (qd, J= 7.1, 1.2 Hz, 2H), 4.37 - 4.30 (m, 2H), 3.57 (d, J= 2.4 Hz, IH), 2.63 (s, 3H), 1.48 (t, J= 7.2 Hz, 3H), 1.27 (t, J= 7.0 Hz, 3H). LCMS (M+H) = 434.1.

Ethyl 6-(2-ethoxy-2-oxoacetyl)-7-iodo-5-methylpyrazolo[l,5-a]pyrimidine-2- carboxylate. To a mixture of ethyl 6-(2-ethoxy-l-hydroxy-2-oxoethyl)-7-iodo-5- methylpyrazolo[l,5-a]pyrimidine-2-carboxylate (3.7 g, 6.41 mmol) in (¾(¾ (80 mL) was added Dess-Martin Periodinane (2.72 g, 6.41 mmol) and the resulting mixture was stirred at rt for 1 h. The reaction mixture was diluted with ethyl acetate (500 mL) and washed with sat. aq. NaHC0₃ solution ( 100 mL), dried (Na₂S0₄), filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (5-70 % EtOAc/hexane) to afford the desired ethyl 6-(2-ethoxy-2- oxoacetyl)-7-iodo-5-methylpyrazolo[l,5-a]pyrimidine-2-carboxylate (2.5 g, 5.8 mmol, 91 % yield) as an off-white solid. IH NMR (400 MHz, CDC1₃) δ 7.36 (s, IH), 4.50 (dq, J= 14.5, 7.1 Hz, 4H), 2.56 (s, 3H), 1.46 (t, J= 7.2 Hz, 3H), 1.48 (t, J= 7.2 Hz, 3H). LCMS (M+H) = 431.87.

(S) -Ethyl 6-(2-ethoxy-l-hydroxy-2-oxoethyl)-7-iodo-5-methylpyrazolo[l,5- aJpyrimidine-2-carboxylate. To a stirred yellow solution of ethyl 6-(2-ethoxy-2- oxoacetyl)-7-iodo-5-methylpyrazolo[l,5-a]pyrimidine-2-carboxylate (6.4 g, 14.8 mmol) in anhydrous toluene (300 mL) was added 1.1M (R)- 1-methy 1-3,3 - diphenylhexahydropyrrolo[l,2-c][l,3,2]oxazaborole/toluene (5.40 mL, 5.94 mmol). The mixture was cooled to -35 °C and a solution of 50% catechoborane/toluene (5.09 mL, 20.78 mmol) was added over the course of 10 min. After 30 min, the reaction mixture was slowly warmed to -15 °C and stirred for additional 2 h, then diluted with EtOAc (600 mL) and sat.aq. a2C03 (100 mL). The mixture was stirred vigorously for 30 min, and the organic phase was washed with sat. aq. a₂C0₃ (2 X 100 mL), dried ( a₂S04), filtered, concentrated. The residue was purified by silica gel chromatography (5-100% EtOAc/hexane) to afford the desired (S)-ethyl 6-(2-ethoxy- l-hydroxy-2-oxoethyl)-7-iodo-5-methylpyrazolo[l,5-a]pyrimidine-2-carboxylate (5.3 g, 12.2 mmol, 82 % yield) as an off-white solid. 1H NMR (500 MHz, CDC1₃) δ 7.33 (s, 1H), 5.75 (d, J= 2.4 Hz, 1H), 4.52 (qd, J= 7.1, 1.1 Hz, 2H), 4.38-4.29 (m, 2H), 3.59 (d, J= 2.4 Hz, 1H), 2.63 (s, 3H), 1.48 (t, J= 7.2 Hz, 3H), 1.27 (t, J= 7.2 Hz, 3H). LCMS (M+H) = 434.2.

(S) -Ethyl 6-(l-( tert-butoxy)-2-ethoxy-2-oxoethyl)- 7-iodo-5- methylpyrazolo[l,5-a]pyrimidine-2-carboxylate. To a stirred solution of (S)-ethyl 6- (2-ethoxy- 1 -hydroxy-2-oxoethyl)-7-iodo-5-methylpyrazolo[ 1 ,5-a]pyrimidine-2- carboxylate (5.3 g, 12.2 mmol) in CH2CI2 (150 mL) and t-butyl acetate (105 mL) at rt was added perchloric acid (3.15 mL, 36.7 mmol). The reaction flask was sealed. After stirring for 3 h, the reaction mixture was diluted with CH2CI2 (100 mL), carefully quenched with sat. aq. NaHCCh (50 mL). The organic layer was separated and washed with brine (100 mL), dried ( a₂S04), filtered and concentrated in vacuo to give a yellow liquid. This crude product was purified by flash column chromatography on a silica gel column using (10-50% EtOAc/Hex as eluant) to afford the desired (S)-ethyl 6-(l-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-iodo-5- methylpyrazolo[l,5-a]pyrimidine-2-carboxylate (4.5 g, 8.28 mmol, 67.7 % yield) as viscous oil. In addition, 700 mg of starting material was recovered. 1H NMR (500 MHz, CDCI₃) δ 7.31 (s, 1H), 5.56 (s, 1H), 4.51 (q, J= 7.1 Hz, 2H), 4.26-4.16 (m, 2H), 2.71 (s, 3H), 1.48 (t, J= 7.2 Hz, 3H), 1.30 (s, 9H), 1.23 (t, J= 7.0 Hz, 3H). LCMS (M+H) = 490.0.

2-(8-fluoro-5-methylchroman-6-yl)-4, 4, 5, 5-tetramethyl-l, 3, 2 dioxaborolane. The title compound was prepared from the known procedure as described in the reference WO 2009/062285.

6-((S)-l-(tert-Butoxy)-2-ethoxy-2-oxoethyl)-7-(8-fluoro-5-methylchroman-6- yl)-5-methylpyrazolo[l,5-a]pyrimidine-2-carboxylate. A mixture of (S)-ethyl 6-(l- (tert-butoxy)-2-ethoxy-2-oxoethyl)-7-iodo-5-methylpyrazolo[l,5-a]pyrimidine-2- carboxylate (4.5 g, 9.20 mmol), 2-(8-fluoro-5-methylchroman-6-yl)-4,4,5,5- tetramethyl-l,3,2-dioxaborolane (3.22 g, 11.04 mmol) and 2N Na₂C0₃ (9.20 mL, 18.39 mmol) in DMF (100 mL) was degassed and flushed with 2 for 30 min. Tetrakis(triphenylphosphine)palladium(0) (0.744 g, 0.644 mmol) was then added and the reaction was flushed with 2 for another 15 min. The mixture was then heated at 100°C for 16 h. At this point LCMS indicated completion of reaction and appearance of desired product. After cooling to rt, water was added (50 mL) and the mixture was extracted with ether (2X 200 mL). The organic phase was washed with brine (100 mL), dried ( a₂S04), filtered and concentrated in vacuo. The residue was then purified by silica gel chromatography (5-60% EtOAc/hexane) to afford ethyl 6-((S)- l-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(8-fluoro-5-methylchroman-6-yl)-5- methylpyrazolo[l,5-a]pyrimidine-2-carboxylate (4 g, 7.58 mmol, 82 % yield) as mixture of atrope isomers (approx 10% of minor atrope isomer was present). 1H NMR (500 MHz, CDC1₃) δ 7.10 (s, 1H), 6.87 (d, J= 10.7 Hz, 1H), 5.00 (s, 1H), 4.41 (qd, J= 7.1, 3.1 Hz, 2H), 4.35 (dd, J= 5.2, 4.0 Hz, 2H), 4.14 (q, J= 7.2 Hz, 2H), 2.80 (s, 3H), 2.79-2.73 (m, 2H), 2.23-2.15 (m, 2H), 1.82 (s, 3H), 1.41 (t, J= 7.2 Hz, 3H), 1.22-1.19 (m, 4H), 1.18 (s, 9H). LCMS (M+H) = 528.4.

6-((S)-l-(tert-Butoxy)-2-ethoxy-2-oxoethyl)-7-(8-fluoro-5-methylchroman-6- yl)-5-methylpyrazolo[l,5-a]pyrimidine-2-carboxylic acid. To a solution of ethyl 6- ((S)-l-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(8-fluoro-5-methylchroman-6-yl)-5- methylpyrazolo[l,5-a]pyrimidine-2-carboxylate (4 g, 6.07 mmol) in THF (40 mL) was added IN NaOH (6.07 mL, 6.07 mmol) and the resulting mixture was stirred at rt for 16 h. At this point the LCMS indicated about 70% conversion, so additional IN NaOH (2.5 mL, 2.5 mmol) was added and the mixture was stirred for another 2 h. At this point LCMS indicated progression of reaction (-90% conversion) along with small amount of di-acid. Water (20 mL) was then added to the reaction mixture and it was acidified with IN HC1 (10 mL). This aqueous solution was extracted with ether (2 x 100 mL), washed with brine (50 mL), dried (Na₂S0₄), filtered and concentrated in vacuo to afford 6-((S)-l-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(8-fluoro-5- methylchroman-6-yl)-5-methylpyrazolo[l,5-a]pyrimidine-2-carboxylic acid (2.7 g, 5.41 mmol, 89 % yield) as off-white solid. 1H NMR (500 MHz, CDC1₃) δ 7.21 (s, 1H), 6.85 (d, J = 10.7 Hz, 1H), 5.00 (s, 1H), 4.36 (t, J= 4.4 Hz, 2H), 4.19-4.12 (m, 2H), 2.81 (s, 3H), 2.80-2.74 (m, 2H), 2.20 (dd, J = 6.3, 4.1 Hz, 2H), 1.83 (s, 3H), 1.24- 1.20 (m, 3H), 1.18 (s, 9H). LCMS (M+H) = 500.4.

(2S) -ethyl 2-tert-butoxy-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2- ((2-(trimethylsilyl)ethoxy)carbonylamino)pyrazolo[l,5-a]pyrimidin-6-yl)acetate. A mixture of 6-((S)-l-(tert-butoxy)-2-ethoxy-2-oxoethyl)-7-(8-fluoro-5- methylchroman-6-yl)-5-methylpyrazolo[l,5-a]pyrimidine-2-carboxylic acid (3.40 g, 5.79 mmol), diphenylphosphoryl azide (1.50 mL, 6.94 mmol), 2- (trimethylsilyl)ethanol (1.66 mL, 11.6 mmol), triethylamine (0.968 mL, 6.94 mmol) in toluene (100 mL) was refluxed for 16 h. It was then concentrated in vacuo. The residue was purified by biotage eluting with 20% EtOAc/hexane to isolate 2.5g (70%) of (2S)-ethyl 2-tert-butoxy-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2- ((2-(trimethylsilyl)ethoxy)carbonylamino)pyrazolo[ 1 ,5-a]pyrimidin-6-yl)acetate as off-white solid. 1H NMR (500MHz, CDC1₃) δ 7.25 (s, 1H), 6.89 (s, 1H), 6.87 (d, J =6.9 Hz, 1H), 4.90 (s, 1H), 4.34 (m, 2H), 4.30 (m, 2H), 4.13 (d, J =7.1 Hz, 2H), 2.84-2.63 (m, 5H), 2.18 (m., 2H), 1.84 (s, 3H), 1.20 (t, J =7.1 Hz, 3H), 1.17(s, 9H), 1.05 (m, 2H), 0.07 (s, 9H). LCMS (M+H) = 615.4.

(2S) -ethyl 2-(2-amino-7-(8-fluoro-5-methylchroman-6-yl)-5- methylpyrazolo[l,5-a]pyrimidin-6-yl)-2-tert-butoxyacetate. A mixture of (2S)-ethyl 2-tert-butoxy-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2-((2-

(trimethylsilyl)ethoxy)carbonylamino)pyrazolo[l,5-a]pyrimidin-6-yl)acetate (2.3 g, 3.74 mmol), 1M TBAF (4.49 mL, 4.49 mmol) in THF (20 mL) was stirred at rt for 3h. It was then concentrated, diluted with water, and extracted with EtOAc. The organic phase was washed with water, dried over MgS0₄, filtered and concentrated to yield 1.5 g (85%) of (2S)-ethyl 2-(2-amino-7-(8-fluoro-5-methylchroman-6-yl)-5- methylpyrazolo[l,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetate as a oil which solidified upon standing for one day. 1H NMR (500 MHz, CDC1₃) δ 6.87 (d, J =10.56 Hz, 1H), 5.88 (s,lH), 4.85 (s, 1H), 4.33 ( t, J =5.04 Hz, 2H), 4.08-4.14 ( m, 4H), 2.76 ( t, J =6.38 Hz, 2H), 2.71 (s, 3 H), 2.13-2.21 (m, 2H), 1.87 (s, 3H), 1.20 (t, J =7.17 Hz, 3H), 1.16 (s, 9H). LCMS (M+H) = 471.36.

Example 1

(2S)-2-(2-amino-7-(8-fluoro-5-methylchroman-6-yl)-5-methylpyrazolo[l,5- a]pyrimidin-6-yl)-2-tert-butoxyacetic acid. A mixture of (2S)-ethyl 2-(2-amino-7-(8- fluoro-5-methylchroman-6-yl)-5-methylpyrazolo[l,5-a]pyrimidin-6-yl)-2-(tert- butoxy)acetate (1.20 g, 2.55 mmol), I aOH (3.83 mL, 3.83 mmol) in EtOH (20 mL) was stirred at rt for 16h. LCMS indicated a small amount of starting material remaining, therefore, the reaction mixture was heated at 60°C for 2 h. At this time, LCMS indicated that the ester hydrolysis was complete. The reaction mixture was then concentrated in vacuo, and the residue was adjusted to pH=4 using IN HC1. A white precipitate formed and was collected by filtration, washed with water, and dried in vacuo to obtain (2S)-2-(2-amino-7-(8-fluoro-5-methylchroman-6-yl)-5- methylpyrazolo[l,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetic acid (1.06 g, 2.16 mmol, 85 % yield) as a off-white solid. 1H NMR (500 MHz, CDC1₃) δ 6.90 (d, J = 10.56 Hz, 1H), 5.91 (s, 1H), 4.97 (s, 1H), 4.26-4.35 (m, 2H), 2.74 (m, 2H), 2.65 (s, 3H), 2.11-2.18 (m, 2H), 1.95 (s, 3H), 1.21 (s, 9H). LCMS (M+H) = 443.23.

General procedure for the preparation amides and carbamates: A mixture of 2S)-2-(2-amino-7-(8-fluoro-5-methylchroman-6-yl)-5-methylpyrazolo[l,5- a]pyrimidin-6-yl)-2-(tert-butoxy)acetic acid (22 mg, 0.050 mmol), 3- cyclopentylpropanoyl chloride (8.79 mg, 0.055 mmol), Hunig's Base (0.026 mL, 0.15 mmol) in THF (2 mL) was stirred at rt for 16 h. It was then concentrated in vacuo and purified by prep HPLC (TFA/MeOH), the desired fractions were combined and adjusted to pH=6 using a few drops of IN NaOH. The residue was then acidified to pH=4 using a few drops of IN HC1. This solution was extracted with EtOAc. The organic phase was dried over MgS0₄, filtered, and concentrated in vacuo to obtain (10 mg, 35%) of (2S)-2-tert-butoxy-2-(2-(3-cyclopentylpropanamido)-7-(8-fluoro-5- methylchroman-6-yl)-5-methylpyrazolo[l,5-a]pyrimidin-6-yl)acetic acid as white solid.

Example 2 (2S)-2-tert-butoxy-2-(2-(3-cyclopentylpropanamido)-7-(8-fluoro-5- methylchroman-6-yl)-5-methylpyrazolo[ 1 ,5-a] pyrimidin-6-yl)acetic acid. IH NMR (500MHz, CDC1₃) δ = 7.95 (br. s., IH), 7.16 (s, IH), 6.89 (d, J = 10.4 Hz, IH), 5.02 (s, IH), 4.43-4.26 (m, 2H), 2.75 (d, J =3.0 Hz, 2H), 2.71 (s, 3H), 2.35 (t, J =7.3 Hz, 2H), 2.20-2.13 (m, 2H), 1.92 (s, 3H), 1.85-0.90 (m, 11H), 1.22 (s, 9H). LCMS (M+H) = 567.38.

The following compounds were prepared according to the general procedure described above using Example 1 and appropriate acylating reagent.

Example 3

(2S)-2-tert-butoxy-2-(7-(8-fluoro-5-methylchroman-6-yl)-2-(2-(4- fluorophenyl)acetamido)-5-methylpyrazolo[ 1, 5 -a]pyrimidin-6-yl) acetic acid. ^XH NMR (400 MHz, CDCI₃) δ 8.37 (s, IH), 7.35-7.22 (m, 2H), 7.17 (s, IH), 7.11-6.98 (m, 2H), 6.84 (d, J= 10.5 Hz, IH), 5.00 (s, IH), 4.39-4.22 (m, 2H), 3.68 (s, 2H), 2.81-2.63 (m, 5H), 2.21-2.07 (m, 2H), 1.88 (s, 3H), 1.24-1.16 (s, 9H). LCMS (M+H) = 579.4.

Example 4 (2S)-2-tert-butoxy-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2-(2- phenylacetamido)pyrazolo[ 1, 5-a]pyrimidin-6-yl) acetic acid. ^XH NMR (500 MHz, CDC1₃) δ 8.39 (s, IH), 7.40-7.34 (m, 2H), 7.33-7.27 (m, 3H), 7.19 (s, IH), 6.87-6.80 (m, IH), 4.98 (s, IH), 4.35-4.25 (m, 2H), 3.73 (s, 2H), 2.75-2.66 (m, 5H), 2.20-2.08 (m, 2H), 1.87 (s, 3H), 1.20 (s, 9H). LCMS (M+H) = 561.30.

Example 5

(2S)-2-tert-butoxy-2-(7-(8-fluoro-5-methylchroman-6-yl)-2-(3- fluorobenzamido)-5-methylpyrazolo[l,5-a]pyrimidin-6-yl)acetic acid. ^XH NMR (500 MHz, CDCI3) δ 8.92 (s, IH), 7.64 (d, J= 7.9 Hz, 2H), 7.49-7.39 (m, IH), 7.28-7.20 (m, 2H), 6.83 (d, J= 10.1 Hz, IH), 5.06-4.91 (m, IH), 4.41-4.22 (m, 2H), 2.73 (s, 5H), 2.15 (m, 2H), 1.85 (s, 3H), 1.19 (s, 9H). LCMS (M+H) = 565.40.

Example 6

(2S)-2-tert-butoxy-2-(7-(8-fluoro-5-methylchroman-6-yl)-2-(3- methoxybenzamido)-5-methylpyrazolo[ 1, 5-a]pyrimidin-6-yl)acetic acid. ^XH NMR (500MHz, CDCI3) δ 8.76 (s, IH), 7.47 (br. s., IH), 7.44-7.39 (m, IH), 7.39-7.34 (m, IH), 7.32 (s, IH), 7.13-7.07 (m, IH), 6.88 (d, J= 10.6 Hz, IH), 5.03 (s, IH), 4.33 (m, 2H), 3.87 (s, 3H), 2.74 (m, 5H), 1.90 (s, 3H), 2.22-2.10 (m, 2H), 1.22 (s, 9H). LCMS (M+H) = 577.36.

Example 7

(2S)-2-(2-(3-(benzyloxy)benzamido)-7-(8-fluoro-5-methylchroman-6-yl)-5- methylpyrazolo[l,5-a]pyrimidin-6-yl)-2-tert-butoxyacetic acid. ^XH NMR (500 MHz, CDC1₃) δ 8.70 (s, 1H), 7.57 (br. s., 1H), 7.51-7.34 (m, 7H), 7.32 (s, 1H), 7.21-7.13 (m, 1H), 6.96-6.86 (m, 1H), 5.14 (s, 2H), 5.04 (s, 1H), 4.33 (m, 2H), 2.74 (m, 5H), 2.24-2.11 (m, 2H), 1.92 (s, 3H), 1.23 (s, 9H). LCMS (M+H) = 653.31.

Example 8

(2S)-2-tert-butoxy-2-(2-(3-cyanobenzamido)-7-(8-fluoro-5-methylchroman-6- yl)-5-methylpyrazolo[l,5-a]pyrimidin-6-yl)acetic acid. ^XH NMR (500 MHz, CDCI₃) δ 9.50 (br. s., 1H), 8.26 (br. s., 1H), 8.16 (d, J= 7.3 Hz, 1H), 7.85 (d, J= 7.3 Hz, 1H), 7.69-7.59 (m, 1H), 7.36 (br. s., 1H), 6.85 (d, J= 10.4 Hz, 1H), 5.04 (br. s., 1H), 4.33 (br. s., 2H), 2.77 (br. s., 5H), 2.25-2.09 (m, 2H), 1.91 (br. s., 3H), 1.22 (br. s., 9H). LCMS (M+H) = 572.27.

Example 9

(2S)-2-(2-(2-(benzyloxy)acetamido)-7-(8-fluoro-5-methylchroman-6-yl)-5- methylpyrazolo[l,5-a]pyrimidin-6-yl)-2-tert-butoxyacetic acid. ^XH NMR (500 MHz, CDC1₃) δ 9.08 (s, 1H), 7.44-7.32 (m, 5H), 7.21 (s, 1H), 6.89 (d, J= 10.6 Hz, 1H), 5.03 (s, 1H), 4.63 (s, 2H), 4.38-4.29 (m, 2H), 4.12 (s, 2H), 2.74 (m, 5H), 2.23-2.12 (m, 2H), 1.90 (s, 3H), 1.22 (s, 9H). LCMS (M+H) = 591.32.

Example 10

(2S)-2-tert-butoxy-2-(2-(3, 4-dimethylbenzamido)- 7-( 8-fluoro-5- methylchroman-6-yl)-5-methylpyrazolo[ 1, 5-a]pyrimidin-6-yl)acetic acid. ^XH NMR (500 MHz, CDCI₃) δ 8.86 (s, 1H), 7.70 (s, 1H), 7.62 (d, J= 7.9 Hz, 1H), 7.34 (s, 1H), 7.23 (d, J= 7.9 Hz, 1H), 6.89 (d, J= 10.6 Hz, 1H), 5.03 (s, 1H), 4.38-4.27 (m, 2H), 2.74 (s, 5H), 2.33 (d, J= 3.5 Hz, 6H), 2.21-2.11 (m, 2H), 1.91 (s, 3H), 1.22 (s, 9H). LCMS (M+H) = 575.33.

Example 11

(2S)-2-tert-butoxy-2-(2-(3-tert-butyl-l-methyl-lH-pyrazole-5-carboxamido)- 7-(8-fluoro-5-methylchroman-6-yl)-5-methylpyrazolo[l,5-a]pyrimidin-6-yl)acetic acid. ¾ NMR (500 MHz, CDC1₃) δ 8.99 (s, IH), 7.27 (s, IH), 6.87 (d, J= 10.4 Hz, IH), 6.58 (s, IH), 5.03 (s, IH), 4.36-4.30 (m, 2H), 4.20 (s, 3H), 2.76 (s, 5H), 2.20- 2.13 (m, 2H), 1.91 (s, 3H), 1.30 (s, 9H), 1.22 (s, 9H). LCMS (M+H) = 607.36.

Example 12

(2S)-2-tert-butoxy-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2-(4- phenylbutanamido)pyrazolo[ 1,5 -a] pyrimidin-6-yl) acetic acid. ^XH NMR (500 MHz, CDCI₃) δ 8.30 (br. s., IH), 7.29 (s, 2H), 7.23-7.15 (m, 4H), 6.90-6.83 (m, IH), 5.01 (s, IH), 4.35-4.28 (m, 2H), 2.72 (m, 7H), 2.39-2.33 (m, 2H), 2.19-2.12 (m, 2H), 2.10- 2.03 (m, 2H), 1.90 (s, 3H), 1.21 (s, 9H). LCMS (M+H) = 589.30.

Example 13

(2S)-2-tert-butoxy-2-(7-(8-fluoro-5-methylchroman-6-yl)-2-(2-((2R,5S)-2- isopropyl-5-methylcyclohexyloxy)acetamido)-5-methylpyrazolo[l,5-a]pyrimidin-6- yl)acetic acid. ¾ NMR (400 MHz, CDC1₃) δ 9.00 (br. s., 1H), 7.22 (s, 1H), 6.98- 6.85 (m, 1H), 5.03 (s, 1H), 4.34 (br. s., 2H), 4.26-4.15 (m, 1H), 4.09-4.01 (m, 1H), 3.27-3.14 (m, 1H), 2.84-2.66 (m, 5H), 2.17 (br. s., 3H), 2.04 (d, J = 11.3 Hz, 1H), 1.91 (br. s., 3H), 1.67 (br. s., 2H), 1.45-1.13 (m, 11H), 1.05-0.83 (m, 9H), 0.81-0.72 (m, 3H). LCMS (M+H) = 639.49.

Example 14

(2S)-2-tert-butoxy-2-(2-(3-ethoxybenzamido)-7-(8-fluoro-5-methylchroman-6- yl)-5-methylpyrazolo[l,5-a]pyrimidin-6-yl) acetic acid. ^XH NMR (500 MHz, DMSO- d6) 5 11.26 (s, 1H), 7.59 (d, J = 1.5 Hz, 2H), 7.44-7.30 (m, 1H), 7.14-7.03 (m, 3H), 4.73 (s, 1H), 4.31-4.20 (m, 2H), 4.10 (q, J = 7.0 Hz, 2H), 2.68 (s, 5H), 2.13-1.96 (m, 2H), 1.82 (s, 3H), 1.35 (s, 3H), 1.07 (s, 9H). LCMS (M+H) = 591.5.

Example 15

(2S)-2-tert-butoxy-2-(2-(3, 4-dimethoxybenzamido)-7-(8-fluoro-5- methylchroman-6-yl)-5-methylpyrazolo[ 1, 5-a]pyrimidin-6-yl)acetic acid.

(500 MHz, DMSO-d₆) δ 11.12 (s, 1H), 7.77-7.63 (m, 2H), 7.08 (d, J = 11.3 Hz, 1H), 7.06-7.02 (m, 2H), 4.73 (br. s., 1H), 4.26 (d, J = 3.1 Hz, 2H), 3.83 (s, 6H), 2.79-2.63 (m, 5H), 2.14-1.97 (m, 2H), 1.82 (s, 3H), 1.07 (s, 9H). LCMS (M+H) = 607.44.

Example 16

-butoxy-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2-(3- phenylpropanamido)pyrazolo [1,5 -a] pyrimidin-6-yl) acetic acid. ^XH NMR (500 MHz, DMSO-d₆) δ 10.94 (s, 1H), 7.30-7.25 (m, 2H), 7.24-7.20 (m, 2H), 7.20-7.15 (m, 1H), 7.03 (d, J = 11.3 Hz, 1H), 6.84 (s, 1H), 4.72 (br. s., 1H), 4.25 (d, J = 3.1 Hz, 2H), 2.90-2.83 (m, 2H), 2.74-2.59 (m, 7H), 2.12-1.95 (m, 2H), 1.78 (s, 3H), 1.07 (s, 9H). LCMS (M+H) = 575.4.

Example 17

(2S)-2-tert-butoxy-2-(7-(8-fluoro-5-methylchroman-6-yl)-2-hexanamido-5- methylpyrazolo[l,5-a]pyrimidin-6-yl) acetic acid. ^XH NMR (500 MHz, DMSO-d6) δ 10.86 (s, 1H), 7.04 (d, J = 11.0 Hz, 1H), 6.84 (s, 1H), 4.77-4.66 (m, 1H), 4.31-4.19 (m, 2H), 2.65 (s, 5H), 2.35-2.24 (m, 2H), 2.11-1.97 (m, 2H), 1.78 (s, 3H), 1.61-1.49 (m, 2H), 1.27 (d, J = 7.6 Hz, 4H), 1.07 (s, 9H), 0.86 (t, J = 7.0 Hz, 3H). LCMS (M+H) = 541.47.

Example 18

(2S)-2-tert-butoxy-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2-(9-oxo- 9H-fluorene-3-carboxamido)pyrazolo[l,5-a]pyrimidin-6-yl) acetic acid. ^XH NMR (500 MHz, DMSO-d₆) δ 11.80 (s, 1H), 7.76-7.65 (m, 3H), 7.62-7.52 (m, 2H), 7.47- 7.37 (m, 2H), 7.13 (s, 1H), 7.09 (d, J = 11.3 Hz, 1H), 4.79 (s, 1H), 4.31-4.12 (m, 2H), 2.71 (s, 3H), 2.73-2.56 (m, 2H), 2.10-1.93 (m, 2H), 1.81 (s, 3H), 1.09 (s, 9H). LCMS (M+H) = 649.48.

Example 19

(2S)-2-tert-butoxy-2-(2-(2-ethoxybenzamido)-7-(8-fluoro-5-methylchroman-6- yl)-5-methylpyrazolo[l,5-a]pyrimidin-6-yl) acetic acid. ^XH NMR (500 MHz, DMSO- d₆) δ 10.81 (s, 1H), 7.73-7.68 (m, 1H), 7.50-7.45 (m, 1H), 7.13 (d, J = 8.2 Hz, 1H), 7.06-7.00 (m, 2H), 6.92 (s, 1H), 4.75 (br. s., 1H), 4.29-4.21 (m, 2H), 4.14 (q, J = 7.0 Hz, 2H), 2.78-2.59 (m, 5H), 2.13-1.97 (m, 2H), 1.80 (s, 3H), 1.32-1.27 (m, 3H), 1.08 (s, 9H). LCMS (M+H) = 591.45.

Example 20

(2S)-2-tert-butoxy-2-(2-(7, 7-dimethyloctanamido)-7-(8-fluoro-5- methylchroman-6-yl)-5-methylpyrazolo[ 1, 5-a]pyrimidin-6-yl)acetic acid. ^XH NMR (500 MHz, DMSO-d₆) δ 10.33-10.17 (m, 1H), 7.08 (s, 1H), 6.93-6.86 (m, 1H), 4.74 (s, 1H), 4.31-4.19 (m, 2H), 2.74-2.61 (m, 5H), 2.12-1.96 (m, 2H), 1.79 (br. s., 3H), 1.77-1.68 (m, 1H), 1.48-1.36 (m, 1H), 1.27-1.09 (m, 7H), 1.07 (s, 9H), 0.94 (m, 1H), 0.89-0.67 (m, 9H). LCMS (M+H) = 597.57.

Example 21

(2S)-2-tert-butoxy-2-(2-(2-cyclopentylacetamido)-7-(8-fluoro-5- methylchroman-6-yl)-5-methylpyrazolo[ 1, 5-a]pyrimidin-6-yl)acetic acid. ^XH NMR (500 MHz, DMSO-d₆) δ 10.85 (s, IH), 7.04 (d, J = 11.3 Hz, IH), 6.84 (s, IH), 4.71 (s, IH), 4.25 (br. s., 2H), 2.74-2.61 (m, 5H), 2.34-2.27 (m, 2H), 2.20 (dt, J =15.2, 7.5 Hz, IH), 2.12-1.96 (m, 2H), 1.79 (s, 3H), 1.75-1.67 (m, 2H), 1.63-1.54 (m, 2H), 1.54- 1.43 (m, 2H), 1.18-1.09 (m, 2H), 1.07 (s, 9H). LCMS (M+H) = 553.43.

Example 22

(2S)-2-tert-butoxy-2-(2-(2,2-difluorobenzo[d] [l,3]dioxole-5-carboxamido)-7- (8-fluoro-5-methylchroman-6-yl)-5-methylpyrazolo[l,5-a]pyrimidin-6-yl)acetic acid. ¾ NMR (500 MHz, DMSO-d₆) δ 11.37 (s, IH), 8.05 (d, J = 1.8 Hz, IH), 7.94 (dd, J = 8.5, 1.8 Hz, IH), 7.53 (d, J = 8.5 Hz, IH), 7.10 (d, J = 11.0 Hz, IH), 7.04 (s, IH), 4.77 (s, IH), 4.30-4.22 (m, 2H), 2.74-2.63 (m, 5H), 2.13-1.99 (m, 2H), 1.81 (s, 3H), 1.08 (s, 9H). LCMS (M+H) = 627.40.

Example 23

(2S)-2-tert-butoxy-2-(7-(8-fluoro-5-methylchroman-6-yl)-2-(3-(4- methoxyphenyl)propanamido)-5-methylpyrazolo[ 1, 5-a]pyrimidin-6-yl)acetic acid. ¾ NMR (500 MHz, DMSO-d₆) δ 10.90 (s, IH), 7.13 (d, J = 8.5 Hz, 2H), 7.02 (d, J = 11.3 Hz, IH), 6.87-6.75 (m, 3H), 4.69 (s, IH), 4.35^1.11 (m, 2H), 3.71 (s, 3H), 2.81 (t, J = 7.6 Hz, 2H), 2.73-2.61 (m, 5H), 2.61-2.55 (m, 2H), 2.11-1.98 (m, 2H), 1.78 (s, 3H), 1.06 (s, 9H). LCMS (M+H) = 605.46.

Example 24

(2S)-2-tert-butoxy-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2-(3- methyl-2-phenoxybutanamido)pyrazolo[l,5-a]pyrimidin-6-yl)acetic acid. A mixture of two diastereomers. LCMS (M+H) = 619.50.

Example 25

(2S)-2-tert-butoxy-2-(2-(2-cyclohexylacetamido)-7-(8-fluoro-5- methylchroman-6-yl)-5-methylpyrazolo[ 1, 5-a]pyrimidin-6-yl)acetic acid. ^XH NMR (500 MHz, DMSO-d₆) δ 10.84 (s, 1H), 7.03 (d, J = 11.3 Hz, 1H), 6.84 (s, 1H), 4.62 (s, 1H), 4.25 (br. s., 2H), 2.74-2.61 (m, 5H), 2.22-2.16 (m, 2H), 2.11-1.98 (m, 2H), 1.79 (s, 3H), 1.77-1.71 (m, 1H), 1.69-1.54 (m, 5H), 1.27-1.08 (m, 3H), 1.06 (s, 9H), 0.97-0.86 (m, 2H). LCMS (M+H) = 567.49.

Example 26

(2S)-2-tert-butoxy-2-(2-(2-(3,4-dichlorophenyl)acetamido)-7-(8-fluoro-5- methylchroman-6-yl)-5-methylpyrazolo[ 1, 5-a]pyrimidin-6-yl)acetic acid. ^XH NMR (500 MHz, DMSO-d₆) δ 11.24 (s, 1H), 7.63-7.53 (m, 2H), 7.29 (dd, J = 8.2, 1.8 Hz, 1H), 7.06 (d, J = 11.3 Hz, 1H), 6.88-6.73 (m, 1H), 4.78 (s, 1H), 4.35-4.18 (m, 2H), 3.73-3.61 (m, 2H), 2.79-2.62 (m, 5H), 2.18-1.96 (m, 2H), 1.80 (s, 3H), 1.08 (s, 9H). LCMS (M+H) = 629.39.

Example 27

(2S)-2-tert-butoxy-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2-(4- phenoxybutanamido)pyrazolo[ 1, 5-a]pyrimidin-6-yl)acetic acid. ^XH NMR (500 MHz, DMSO-d₆) δ 10.88 (s, 1H), 7.27 (t, J = 8.1 Hz, 2H), 6.97 (d, J = 11.3 Hz, 1H), 6.94- 6.88 (m, 3H), 6.79 (s, 1H), 4.51-4.44 (m, 1H), 4.23 (br. s., 2H), 3.97 (t, J = 6.4 Hz, 2H), 2.72-2.61 (m, 5H), 2.50-2.44 (m, 2H), 2.03-1.97 (m, 4H), 1.84 (s, 3H), 1.08- 0.98 (m, 9H). LCMS (M+H) = 605.47.

Example 28

(2S)-2-tert-butoxy-2-(2-(3-cyclohexylpropanamido)-7-(8-fluoro-5- methylchroman-6-yl)-5-methylpyrazolo[ 1, 5-a]pyrimidin-6-yl)acetic acid. LCMS (M+H) = 581.51.

Example 29

(2S)-2-tert-butoxy-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2-(3,4,5- trimethoxybenzamido)pyrazolo[ 1, 5-a]pyrimidin-6-yl)acetic acid. ^XH NMR (500 MHz, DMSO-d₆) δ 11.24 (s, IH), 7.42 (s, 2H), 7.10 (d, J = 11.0 Hz, IH), 7.07 (s, IH), 4.74 (s, IH), 4.35-4.19 (m, 2H), 3.85 (s, 6H), 3.73 (s, 3H), 2.73-2.63 (m, 5H), 2.12-1.97 (m, 2H), 1.82 (s, 3H), 1.07 (s, 9H) LCMS (M+H) = 637.5.

Example 30

(2S)-2-tert-butoxy-2-(2-(2-(l,3-dioxoisoindotin-2-yl)acetamido)-7-(8-fluoro- 5-methylchroman-6-yl)-5-methylpyrazolo[ 1, 5-a]pyrimidin-6-yl)acetic acid. ^XH NMR (500 MHz, DMSO-d₆) δ 11.46 (s, IH), 7.98-7.88 (m, 4H), 7.08 (d, J = 11.0 Hz, IH), 6.76 (s, IH), 4.79 (s, IH), 4.42 (s, 2H), 4.26 (br. s., 2H), 2.74-2.63 (m, 5H), 2.12-1.99 (m, 2H), 1.79 (s, 3H), 1.08 (s, 9H). LCMS (M+H) = 630.4.

Example 31

(2S)-2-(2-(2-(lH-indol-3-yl)-2-oxoacetamido)-7-(8-fluoro-5-methylchroman- 6-yl)-5-methylpyrazolo[ 1, 5-a]pyrimidin-6-yl)-2-tert-butoxyacetic acid. ^XH NMR (500 MHz, DMSO-d₆) δ 12.37 (br. s., 1H), 11.24 (br. s., 1H), 8.62 (s, 1H), 8.24-8.17 (m, 1H), 7.60-7.52 (m, 1H), 7.28 (ddd, J = 7.2, 5.4, 1.4 Hz, 2H), 7.07 (d, J = 11.0 Hz, 1H), 7.02 (s, 1H), 4.80 (s, 1H), 4.26 (t, J = 5.0 Hz, 2H), 2.70 (m, 5H), 2.14-1.98 (m, 2H), 1.81 (s, 3H), 1.09 (s, 9H). LCMS (M+H) = 614.43.

Example 32

(2S)-2-(tert-butoxy)-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2-(((p- tolyloxy)carbonyl)amino)pyrazolo[l,5-a]pyrimidin-6-yl)acetic acid. LCMS (M+H) = 577.29.

Example 33

(2S)-2-(2-(((benzyloxy)carbonyl)amino)-7-(8-fluoro-5-methylchroman-6-yl)- 5-methylpyrazolo[l,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetic acid. LCMS (M+H) = 577.3.

Example 34

(2S)-2-(tert-butoxy)-2-(2-((butoxycarbonyl)amino)-7-(8-fluoro-5- methylchroman-6-yl)-5-methylpyrazolo[ 1, 5-a]pyrimidin-6-yl)acetic acid. LCMS (M+H) = 543.31.

Example 35 (2S)-2-(tert-butoxy)-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2- (((neopentyloxy)carbonyl)amino)pyrazolo[l,5-a]pyrimidin-6-yl)acetic acid. LCMS (M+H) = 557.22. Prepared according to the above procedure for Example 1.

Example 36

(2S)-2-(tert-butoxy)-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2-(((2- (trimethylsilyl)ethoxy)carbonyl)amino)pyrazolo[ 1, 5-a]pyrimidin-6-yl)acetic acid. LCMS (M+H) = 587.6.

Example 37

(2S)-2-(tert-butoxy)-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2-(3-(p- tolyl)ureido)pyrazolo[l,5-a]pyrimidin-6-yl)acetic acid. A mixture of Example 1 (22 mg, 0.050 mmol), l-isocyanato-4-methylbenzene (7.28 mg, 0.055 mmol), Hunig's base (0.026 mL, 0.149 mmol) in THF (2 mL) was stirred at rt for 16 h. It was then concentrated and purified by prep HPLC (TFA/MeOH). The fractions were combined and adjusted pH = 6 using IN NaOH. The residue was adjusted pH = 3-4 by adding 1-2 drops of IN HCl. It was then extracted with EtOAc, dried, filtered and concentrated to obtained Example (18 mg, 60%) as light yellow solid. LCMS (M+H)

576.31.

Example 38

(2S)-2-(2-(benzylamino)-7-(8-fluoro-5-methylchroman-6-yl)-5- methylpyrazolo[l,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetic acid. A mixture of Example 1 (20 mg, 0.045 mmol), benzaldehyde (5.28 mg, 0.050 mmol), acetic acid (0.013 mL, 0.226 mmol) and aCNBH₃ (14.20 mg, 0.226 mmol) in MeOH (2 mL) was stirred at rt for 16h. It was then concentrated and purified by prep HPLC to isolate Example 38 (15 mg, 59% ) as yellow solid. NMR-CDC1₃, LC-MS: consistent with the desired product. 1H NMR (500MHZ, CDCI₃) δ 7.33 (d, J= 4.4 Hz, 5H), 6.85 (d, J= 10.6 Hz, 1H), 5.91 (s, 1H), 4.98 (s, 1H), 4.40 (s, 2H), 4.37 - 4.26 (m, 2H), 2.83 - 2.58 (m, 5H), 2.25 - 2.09 (m, 2H), 1.92 (s, 3H), 1.20 (s, 9H). LCMS (M+H) = 533.38.

The following compounds were prepared according to the general procedure described above using ap

Example 39

(2S)-2-(tert-butoxy)-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2- (phenethylamino)pyrazolo[l,5-a]pyrimidin-6-yl)acetic acid. LCMS (M+H) =

547.27.

Example 40

(2S)-2-(tert-butoxy)-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2-((4- methylphenethyl)amino)pyrazolo[l,5-a]pyrimidin-6-yl)acetic acid. LCMS (M+H) 561.19.

Example 41

(2S)-2-(tert-butoxy)-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2-((3- phenylpropyl)amino)pyrazolo[l,5-a]pyrimidin-6-yl)acetic acid. LCMS (M+H) = 561.33.

Example 42

(2S)-2-(tert-butoxy)-2-(2-((3-cyclopentylpropyl)amino)-7-(8-fluoro-5- methylchroman-6-yl)-5-methylpyrazolo[ 1, 5-a]pyrimidin-6-yl)acetic acid. LCMS (M+H) = 553.25.

Example 43

(2S)-2-(tert-butoxy)-2-(7-(8-fluoro-5-methylchroman-6-yl)-2- (isopentylamino)-5-methylpyrazolo[l,5-a]pyrimidin-6-yl)acetic acid. LCMS (M+H) = 513.15.

Example 44

(2S)-2-(tert-butoxy)-2-(2-(diisopentylamino)-7-(8-fluoro-5-methylchroman-6- yl)-5-methyJpyrazolo[l,5- S (M+H) = 583.13.

Example 45

(2S)-2-(tert-butoxy)-2-(2-((3,3-dimethylbutyl)amino)-7-(8-fluoro-5- methylchroman-6-yl)-5-methylpyrazolo[ 1 ,5-aj ' pyrimidin-6-yl) acetic acid. LCMS (M+H) = 527.05.

Example 46

(2S)-2-(2-(bis(3,3-dimethylbutyl)amino)-7-(8-fluoro-5-methylchroman-6-yl)- 5-methylpyrazolo[l,5-a]pyrimidin-6-yl)-2-(tert-butoxy)acetic acid. LCMS (M+H) = 611.14.

Example 47

(2S)-2-(tert-butoxy)-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2- ((3,5, 5-trimethylhexyl)amino)pyrazolo[ 1, 5 -a]pyrimidin-6-yl) acetic acid. LCMS (M+H) = 569.25.

Example 48

(2S)-2-(tert-butoxy)-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2- ((3,3, 3-trifluoropropyl)amino)pyrazolo[ 1, 5-a]pyrimidin-6-yl)acetic acid. LCMS (M+H) = 539.07.

Example 49

(2S)-2-(tert-butoxy)-2-(2-(cyclopentylamino)-7-(8-fluoro-5-methylchroman-6- yl)-5-methylpyrazolo[ 1, 5- 1.23.

Example 50

(2S)-2-(tert-butoxy)-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2- (piperidin-l-yl)pyrazolo [1,5 -a] pyrimidin-6-yl) acetic acid. LCMS (M+H) = 511.3.

Example 51

(2S)-2-(tert-butoxy)-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2- (pyrrolidin-l-yl)pyrazolo[l,5-a]pyrimidin-6-yl)acetic acid. LCMS (M+H) = 4

Example 52

(2S)-2-(tert-butoxy)-2-(2-((3-cyclopentylpropyl)(methyl)amino)-7-(8-fluoro-5- methylchroman-6-yl)-5-methylpyrazolo[ 1 ,5-a] pyrimidin-6-yl)acetic acid. A mixture of example 1 (20 mg, 0.045 mmol), 3-cyclopentylpropanal (6.84 mg, 0.054 mmol), NaCNBH₃(14.20 mg, 0.226 mmol), acetic acid (0.013 mL, 0.226 mmol) in MeOH (2 mL) was stirred at rt for 2 h. Then added paraformaldehyde (13.57 mg, 0.136 mmol)/H₂0 and stirred at rt for another 2 h. It was then concentrated and purified by prep HPLC to give Example 52 (10 mg, 37%) as yellow solid.. LCMS (M+H) = 567.26.

It will be evident to one skilled in the art that the present disclosure is not limited to the foregoing illustrative examples, and that it can be embodied in other specific forms without departing from the essential attributes thereof. It is therefore desired that the examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing examples, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

Claims

A compound of Formula I

I

where:

R¹ is N(R⁶)(R⁷);

R² is hydrogen, halo, or alkyl; R³ is alkyl, cycloalkyl, or Ar¹; R⁴ is alkyl or haloalkyl; R⁵ is alkyl;

R⁶ is hydrogen, alkyl, haloalkyl, (cycloalkyl)alkyl, (Ar²)alkyl, cycloalkyl,

((Ar²)alkyl)COCO; or R⁶ is ((trialkylsilyl)alkyl)OCO, (benzyloxy)alkylCO, (phenoxyalkyl)CO,

(isoindolinedionyl)alkyl)CO, (((dialkyl)cycloalkoxy)alkyl)CO, (phenoxyalkyl)CO, or (dihalobenzodioxolyl)CO; R⁷ is hydrogen or alkyl; or N(R⁶)(R⁷) taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl, homopiperazinyl, or homomorpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, haloalkyl, hydroxy, alkoxy, or haloalkoxy; and

2. A compound of claim 1 where: R¹ is N(R⁶)(R⁷); R² is hydrogen; R³ is Ar¹;

R⁴ is alkyl; R⁵ is alkyl;

(isoindolinedionyl)alkyl)CO, (((dialkyl)cycloalkoxy)alkyl)CO, (phenoxyalkyl)CO, or (dihalobenzodioxolyl)CO; R⁷ is hydrogen or alkyl; or where N(R⁶)(R⁷) taken together is pyrrolidinyl or piperidinyl, and is substituted with 0-3 substituents selected from halo, alkyl, haloalkyl, hydroxy, alkoxy, and haloalkoxy;

Ar¹ is chromanyl substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, hydroxy, alkoxy, haloalkoxy, phenoxy, benzyloxy, thioalkyl, and acetamido; and Ar² is phenyl, pyrazolyl, indolyl, or fluorenonyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, benzyloxy, and haloalkoxy; or a pharmaceutically acceptable salt thereof.

3. A compound of claim 1 where R² is hydrogen.

4. A compound of claim 1 where R³ is Ar¹.

5. A compound of claim 1 where R⁴ is alkyl.

6. A compound of claim 1 where R⁶ is hydrogen, alkyl, haloalkyl,

(cycloalkyl)alkyl, (Ar²)alkyl, cycloalkyl, (alkyl)CO, ((cycloalkyl)alkyl)CO, (Ar²)CO, ((Ar²)alkyl)CO, ((Ar²)alkyl)OCO, ((Ar²)alkyl)NHCO, or ((Ar²)alkyl)COCO.

7. A compound of claim 1 where N(R⁶)(R⁷) taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl,

homopiperazinyl, or homomorpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, haloalkyl, hydroxy, alkoxy, or haloalkoxy.

8. A compound of claim 7 where N(R⁶)(R⁷) taken together is pyrrolidinyl or piperidinyl, and is substituted with 0-3 substituents selected from halo, alkyl, haloalkyl, hydroxy, alkoxy, and haloalkoxy.

9. A compound of claim 1 where Ar¹ is chromanyl substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, hydroxy, alkoxy, haloalkoxy, phenoxy, benzyloxy, thioalkyl, and acetamido.

10. A compound of claim 1 where Ar² is phenyl, pyrazolyl, indolyl, or fluorenonyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, benzyloxy, and haloalkoxy.

11. A compound of claim 1 where Ar² is phenyl substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, benzyloxy, and haloalkoxy.

12. A composition useful for treating HIV infection comprising a therapeutic amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

13. The composition of claim 12 further comprising a therapeutically effective amount at least one other agent used for treatment of AIDS or HIV infection selected from the group consisting of nucleoside HIV reverse transcriptase inhibitors, non- nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors, and a

pharmaceutically acceptable carrier.

14. A method for treating HIV infection comprising administering a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

15. The method of claim 14 further comprising administering a therapeutically effective amount of at least one other agent used for treatment of AIDS or HIV infection selected from the group consisting of nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitor.